

To NASDAQ OMX Copenhagen A/S Announcement no. 16-14 / Copenhagen, July 1, 2014 Topotarget A/S

Symbion
Fruebjergvej 3
DK-2100 Copenhagen
Denmark
T: +45 39 17 83 92

E: enquiries@topotarget.com Comp reg.: 2569 5771 www.topotarget.com

# Report pursuant to the Danish Securities Trading Act, Section 28a

Pursuant to the Danish Securities Trading Act, Section 28a this is to report the following transactions by members of Topotarget A/S' board of directors and senior management as well as their related parties concerning shares issued by Topotarget A/S and related securities.

Name	Bo Jesper Hansen
Reason for reporting	Chairman of the board of directors
Issuer and ISIN code	Topotarget A/S, DK0060003556
Transaction	Subscription of shares through exercise of
	warrants
Trade Date	July 1, 2014
Market	Nasdaq OMX, Copenhagen
Number of shares	200,000
Market value in DKK	DKK 554,500 based on an average
	subscription price of DKK 2.775 per share
Name	Anker Lundemose
Reason for reporting	Board member
Issuer and ISIN code	Topotarget A/S, DK0060003556
Transaction	Subscription of shares through exercise of
	warrants
Trade Date	July 1, 2014
Market	Nasdaq OMX, Copenhagen
Number of shares	100,000
Market value in DKK	DKK 277,500 based on an average
	subscription price of DKK 2.775 per share
Name	Gisela Schwab
Reason for reporting	Board member
Issuer and ISIN code	Topotarget A/S, DK0060003556
Transaction	Subscription of shares through exercise of
	warrants
Trade Date	July 1, 2014
Market	Nasdaq OMX, Copenhagen
Number of shares	75,000
Market value in DKK	DKK 189,500 based on an average
	subscription price of DKK 2.526 per share



Name	Ingelise Saunders
Reason for reporting	Board member
Issuer and ISIN code	Topotarget A/S, DK0060003556
Transaction	Subscription of shares through exercise of
	warrants
Trade Date	July 1, 2014
Market	Nasdaq OMX, Copenhagen
Number of shares	113,769
Market value in DKK	DKK 321,561 based on an average
	subscription price of DKK 2.826 per share
Name	Jeffrey Buchalter
Reason for reporting	Board member
Issuer and ISIN code	Topotarget A/S, DK0060003556
Transaction	Subscription of shares through exercise of
	warrants
Trade Date	July 1, 2014
Market	Nasdaq OMX, Copenhagen
Number of shares	113,769
Market value in DKK	DKK 321,561 based on an average
	subscription price of DKK 2.826 per share
Name	Karsten Witt
Reason for reporting	Board member
Issuer and ISIN code	Topotarget A/S, DK0060003556
Transaction	Subscription of shares through exercise of
	warrants
Trade Date	July 1, 2014
Market	Nasdaq OMX, Copenhagen
- Idinet	Nasaaq OFIX, copennagen
Number of shares	75,000
	75,000 DKK 189,500 based on an average
Number of shares	75,000
Number of shares Market value in DKK	75,000  DKK 189,500 based on an average subscription price of DKK 2.526 per share
Number of shares  Market value in DKK  Name	75,000  DKK 189,500 based on an average subscription price of DKK 2.526 per share  Anders Fink Vadsholt
Number of shares  Market value in DKK  Name  Reason for reporting	75,000  DKK 189,500 based on an average subscription price of DKK 2.526 per share  Anders Fink Vadsholt CEO
Number of shares  Market value in DKK  Name  Reason for reporting  Issuer and ISIN code	75,000  DKK 189,500 based on an average subscription price of DKK 2.526 per share  Anders Fink Vadsholt  CEO  Topotarget A/S, DK0060003556
Number of shares  Market value in DKK  Name  Reason for reporting	75,000  DKK 189,500 based on an average subscription price of DKK 2.526 per share  Anders Fink Vadsholt  CEO  Topotarget A/S, DK0060003556  Subscription of shares through exercise of
Number of shares  Market value in DKK  Name  Reason for reporting  Issuer and ISIN code  Transaction	75,000  DKK 189,500 based on an average subscription price of DKK 2.526 per share  Anders Fink Vadsholt  CEO  Topotarget A/S, DK0060003556  Subscription of shares through exercise of warrants
Number of shares  Market value in DKK  Name  Reason for reporting  Issuer and ISIN code  Transaction  Trade Date	75,000  DKK 189,500 based on an average subscription price of DKK 2.526 per share  Anders Fink Vadsholt  CEO  Topotarget A/S, DK0060003556  Subscription of shares through exercise of warrants  July 1, 2014
Number of shares  Market value in DKK  Name  Reason for reporting  Issuer and ISIN code  Transaction  Trade Date  Market	75,000  DKK 189,500 based on an average subscription price of DKK 2.526 per share  Anders Fink Vadsholt  CEO  Topotarget A/S, DK0060003556  Subscription of shares through exercise of warrants  July 1, 2014  Nasdaq OMX, Copenhagen
Number of shares  Market value in DKK  Name  Reason for reporting  Issuer and ISIN code  Transaction  Trade Date  Market  Number of shares	75,000  DKK 189,500 based on an average subscription price of DKK 2.526 per share  Anders Fink Vadsholt  CEO  Topotarget A/S, DK0060003556  Subscription of shares through exercise of warrants  July 1, 2014  Nasdaq OMX, Copenhagen  650,000
Number of shares  Market value in DKK  Name  Reason for reporting  Issuer and ISIN code  Transaction  Trade Date  Market	75,000  DKK 189,500 based on an average subscription price of DKK 2.526 per share  Anders Fink Vadsholt  CEO  Topotarget A/S, DK0060003556  Subscription of shares through exercise of warrants  July 1, 2014  Nasdaq OMX, Copenhagen



### Topotarget A/S

For further information, please contact: Anders Vadsholt, CEO – direct: +45 39178345

#### **Background information**

## **About Topotarget**

Topotarget (NASDAQ OMX: TOPO) is a Danish-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to the clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.

#### **Topotarget Safe Harbor Statement**

This announcement may contain forward-looking statements, including statements about Topotarget A/S' expectations to the progression of Topotarget A/S' clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.